Search

Your search keyword '"Ramentol, M"' showing total 12 results
Start Over Author "Ramentol, M" Publication Year Range Last 10 years
12 results on '"Ramentol, M"'

1. Non-differential risk of SARS-CoV-2 infection for members of polling stations on Catalan parliament voting day

Author

Eduardo Hermosilla, Leonardo Mendez-Boo, Francesc Fina, Ermengol Coma, Mireia Fàbregas, Peña-López I, Fuentes A, M Medina-Peralta, Ramentol M, Yolanda Lejardi, and Luis Garcia-Eroles

Subjects
Parliament, media_common.quotation_subject, Incidence (epidemiology), Risk of infection, education, language.human_language, Geography, Voting, Cohort, language, Catalan, Residence, Polling, media_common, Demography
Abstract

We aimed to assess the risk of SARS-CoV-2 infection for polling station members during the Catalan elections in February 2021. We compared the incidence 14 days after the elections between a cohort of polling station members (N= 18,304) and a control cohort paired by age, sex and place of residence. A total of 37 COVID-19 cases (0.2%) were confirmed in the members of the polling stations and 43 (0.23%) in the control group (p-value 0.576). Our study suggests that there was no greater risk of infection for the members of the polling stations.

Published
2021
Full Text
View/download PDF

3. Incidence of first cardiovascular event in Spanish patients with inflammatory rheumatic diseases: prospective data from the CARMA Project

Author

Martin-Martinez M, Castaneda S, Gonzalez-Juanatey C, Sanchez-Alonso F, Garcia-Gomez C, Lopez-Gonzalez R, Babio-Herraiz J, Juan-Mas A, Moreno-Gil M, Sanchez-Gonzalez C, Romera-Baures M, Pinto-Tasende J, Tornero-Molina J, Fabregas-Canales D, Llorca J, Gonzalez-Gay M, de Rabago E, Morales E, Lopez J, Villar N, Sandoval A, Garcia F, De Miquel C, Fernandez M, Codina R, Yoldi B, Ramentol M, Avila G, Barril S, Quesada E, Steiner M, Munoz S, Cobo T, Gamero F, Toron J, Espino P, Ros I, Ibanez M, Murillo C, Sanmarti R, Berman H, Cabrera S, Ruiz V, Paton O, Gutierrez B, Abasolo L, Pina J, Nolla J, Arias M, Vadillo J, de Vicuna R, Nebro A, Arija S, Lopez M, Urena I, Irigoyen M, Cagigal V, Garrido D, Aparicio A, Gomez R, Bautista P, Sanz A, Bachiller J, Manero F, Zorzo F, Ubeda E, Garcia J, Audera C, Medrano M, Pecondon A, Erausquin C, Ojeda S, Quevedo J, Francisco F, Lozano C, Longo F, Gerona D, Fernandez C, Monteagudo I, del Pino J, Gonzalez M, Corrales A, Peiro M, Senabre J, Rosas J, Rotes I, Moreno E, Erra A, Grado D, Calvo J, Rueda A, Moller I, Rodriguez I, Barbadillo C, Raya E, Morales P, Nieto A, Jimenez I, Magro C, Escribano A, Exposito S, Nievas G, Navarro E, Morales M, Bastero I, Consuegra G, Palmou N, Pardo S, Pujol M, Alonso E, Salvador G, Alvarez B, Cantabrana A, Bustabad S, Delgado E, Munoz A, Montero S, Jimenez L, Redondo J, Hernandez T, Polo F, Almagro R, Moreno J, Serret E, Barroso C, Mendez L, Navio M, Carballido C, Pagan E, del Castillo P, Naredo E, Cruz A, Turrion A, Sanchez J, Galindo M, Gonzalez J, Collantes E, Ruiz D, Font P, Bonilla G, Meseguer A, Moreno M, Martinez M, Linares L, Morcillo M, Gomez M, Rivera N, Berrizbeitia O, Vivar M, Riera M, Leon Y, Maymo J, Amirall M, Escolano S, Serrano S, Bona M, Fiter J, Melon J, Espadaler L, Maiz O, Belzunegui J, Banegil I, Diaz C, Valls R, Castellvi I, Bonet M, Ruzafa E, Alen J, Sandoval T, Evrard E, Godo J, Espartero C, Blasco F, Miranda-Filloy J, and CARMA Project Collaborative Grp

Subjects
rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, incidence, cohort study, CARMA project, cardiovascular diseases
Abstract

Objective To determine the incidence and risk factors of first cardiovascular event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD). Methods Analysis of data after 2.5 years of follow-up from the prospective study CARMA project, that includes patients with CIRD [rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA)] and matched individuals without CIRD from 67 hospitals in Spain. CVE cumulative incidence per 1000 patients was calculated after 2.5 years from the start of the project. Weibull proportional hazard model was used to calculate hazard ratio (HR) and 95% confidence interval (95% CI) of the risk factors. Results 2595 (89.1%) patients completed the 2.5 years of follow-up visit. Cumulative incidence of CVE in patients with CIRD was 15.30 cases per 1000 patients (95% CI: 12.93-17.67), being higher in the subgroup with AS; 22.03 (95% CI: 11.01-33.04). Patients with AS (HR: 4.11; 95% CI: 1.07-15.79), those with older age (HR: 1.09; 95% CI: 1.05-1.13), systolic hypertension (HR: 1.02; 95% CI: 1.00-1.04) and long duration of the disease (HR: 1.07; 95% CI: 1.03-1.12) were at higher risk of first CVE during the 2.5 years of follow-up. In contrast, female gender was a protective factor (HR: 0.43; 95% CI: 0.18-1.00). Conclusion Among CIRD patients prospectively followed-up at rheumatology outpatient clinics, those with AS show higher risk of first CVE. Besides cardiovascular risk factors, such as hypertension, being a man and older

Published
2019

4. Hyperlipoproteinaemia(a) in patients with spondyloarthritis: results of the Cardiovascular in Rheumatology (CARMA) project

Author

Garcia-Gomez, C, Martin-Martinez, M, Fernandez C, Castaneda, S, Gonzalez-Juanatey, C, Sanchez-Alonso, F, Gonzalez-Fernandez, M, Sanmarti, R, Garcia-Vadillo, J, Fernandez-Gutierrez, B, Garcia-Arias, M, Manero, F, Senabre, J, Rueda-Cid, A, Ros-Exposito, S, Pina-Salvador, J, Erra-Duran, A, Moller-Parera, I, Llorca, J, Gonzalez-Gay, M, Gonzalez de Rabago, E, Blanco Morales, E, Fernandez Lopez, J, Oreiro Villar, N, Atanes Sandoval, A, Blanco Garcia, F, Alegre De Miquel, C, Gonzalez Fernandez, M, Huguet Codina, R, Yoldi, B, Ramentol, M, Avila, G, Marsal Barril, S, Steiner, M, Munoz, S, Gamero, F, Garcia Toron, J, Moreno Gil, M, Mas, A, Espino, P, Ros, I, Ibanez, M, Murillo, C, Piqueras, J, Berman, H, Cabrera, S, Ruiz, V, Fontsere Paton, O, Fernandez Gutierrez, B, Abasolo, L, Fabregas, M, Romera Baures, M, Nolla, J, Gonzalez-Alvaro, I, Tomero Muriel, E, Garcia de Vicuna, R, Fernandez Nebro, A, Belmonte Lopez, M, Urena, I, Irigoyen, M, Coret Cagigal, V, Lopez Gonzalez, R, Pielfort Garrido, D, Sampedro Alvarez, J, Garcia Aparicio, A, Belmonte Gomez, R, Granados Bautista, P, Hernandez Sanz, A, Sanchez Gonzalez, C, Bachiller, J, Zea, A, Jimenez Zorzo, F, Gimenez Ubeda, E, Marzo Gracia, J, Beltran Audera, C, Medrano, M, Pecondon, A, Erausquin, C, Ojeda, S, Carlos Quevedo, J, Francisco, F, Rodriguez Lozano, C, Babio Herraez, J, Lopez Longo, F, Gerona, D, Gonzalez Fernandez, C, Carreno, L, Monteagudo, I, del Pino, J, Sanchez Gonzalez, M, Corrales, A, Enriqueta Peiro, M, Rosas, J, Rotes, I, Moreno, E, Erra, A, Grado, D, Calvo, J, Rueda, A, Moller, I, Rodriguez, I, Barbadillo, C, Raya, E, Morales, P, Nieto, A, Jimenez, I, Magro, C, Ruibal Escribano, A, Ros Exposito, S, Sanchez Nievas, G, Judez Navarro, E, Sianes Fernandez, M, Garcia Morales, M, Labiano Bastero, I, Consuegra, G, Palmou, N, Martinez Pardo, S, Pujol, M, Riera Alonso, E, Salvador, G, Gonzalez Alvarez, B, Cantabrana, A, Bustabad, S, Delgado, E, Munoz, A, Rodriguez Montero, S, Maria Jimenez, L, Rivera Redondo, J, Gonzalez Hernandez, T, Gonzalez Polo, F, Menor Almagro, R, Moreno, J, Giner Serret, E, Lannuzzelli Barroso, C, Cebrian Mendez, L, Teresa Navio, M, Fernandez Carballido, C, Pagan, E, Mesa del Castillo, P, Naredo, E, Cruz, A, Turrion, A, Mateo, I, Sanchez, J, Galindo, M, Garcia Gonzalez, J, Collantes, E, Ruiz, D, Font, P, Bonilla, G, Lopez Meseguer, A, Moreno, M, Moreno Martinez, M, Beteta Fernandez, M, Linares, L, Morcillo, M, Gonzalez Gomez, M, Aramburu, J, Rivera, N, Fernandez Berrizbeitia, O, Garcia Vivar, M, Riera, M, Maria Leon, Y, Maymo, J, Amirall, M, Iniesta Escolano, S, Sanchez Serrano, S, Lis Bona, M, Fiter, J, Fernandez Melon, J, Espadaler, L, Maiz, O, Belzunegui, J, Banegil, I, Diaz, C, Valls, R, Castellvi, I, Bonet, M, Moreno Ruzafa, E, Calvo Alen, J, Perez Sandoval, T, Revuelta Evrard, E, Godo, J, Fernandez Espartero, C, Navarro Blasco, F, Antonio Gonzalez, J, Miranda-Filloy, J, and CARMA Project Collaborative Grp

Subjects
musculoskeletal diseases, psoriatic arthritis, lipids, stomatognathic diseases, cardiovascular disease, lipoprotein(a), ankylosing spondylitis, spondyloarthritis
Abstract

Objective Cardiovascular (CV) disease is one of the main causes of morbi-mortality in spondyloarthritis (SpA), partially explained by traditional CV risk factors. Information on lipoprotein(a) [Lp(a)], a non-conventional risk factor, in SpA is scarce. In this study we assessed the prevalence of hyperlipoproteinaemia(a) in SpA patients and analysed the possible related factors. Methods A baseline analysis was made of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients and controls included in the CARMA project (CARdiovascular in RheuMAtology), a 10-year prospective study evaluating the risk of CV events in chronic inflammatory rheumatic diseases. A multivariate logistic regression model was performed using hyperlipoproteinaemia( a) (Lp(a) >50 mg/dl) as a dependent variable and adjusting for confounding factors. Results 19.2% (95% CI: 16.80-22.05) of the SpA patients [20.7% (95% CI: 16.91-24.82) of those with AS and 17.7% (95% CI: 14.15-21.75) of those with PsA] and 16.7% (95% CI: 13.23-20.86) of the controls had hyperlipoproteinaemia(a) (p=0.326). Adjusting for age and sex, SpA patients were more likely to have hyperlipoproteinaemia(a) than controls (OR: 1.43, 95% CI: 1.00-2.04; p=0.05), especially those with AS (OR: 1.81, 95% CI: 1.18-2.77; p=0.007). In the adjusted model, apolipoprotein B in all patients, non-steroidal anti-inflammatory drugs in AS, and female sex in PsA, were associated with hyperlipoproteinaemia(a). No disease-specific factors associated with hyperlipoproteinaemia(a) were identified. Conclusion SpA patients show a moderately increased risk of hyperlipoproteinaemia(a) compared to controls, especially those with AS. Lp(a) determination may be of interest to improve the CV risk assessment in SpA patients.

Published
2019

6. OP0088 Categorization of Baseline Systemic Activity at Diagnosis Using the Essdai Disease Activity States (DAS) in Primary Sjögren Syndrome: Association with Poor Outcomes

Author

Brito Zeron, P., primary, Kostov, B., additional, Solans, R., additional, Fraile, G., additional, Caravia-Durán, D., additional, Maure, B., additional, Rascόn, F.-J., additional, Villar-Navas, B., additional, Ripoll, M., additional, Pinilla, B., additional, Fonseca, E., additional, Akasbi, M., additional, Pérez-de-Lis, M., additional, Jiménez-Heredia, I., additional, de la Red, G., additional, Gato, A., additional, Ramentol, M., additional, Ruedas, A., additional, Díaz-Lόpez, B., additional, Pallarés, L., additional, Gheitasi, H., additional, and Ramos-Casals, M., additional

Published
2015
Full Text
View/download PDF

7. SAT0417 Cancer and Primary SjÖgren Syndrome in 1216 Patients (GEAS-SS Registry): Systemic Activity Measured by the Essdai is Related to Hematological, but not Solid Neoplasia

Author

Brito Zeron, P., primary, Kostov, B., additional, Solans, R., additional, Fraile, G., additional, García-Pérez, A., additional, Maure, B., additional, Rascόn, F.-J., additional, Lopez-Dupla, M., additional, Ripoll, M., additional, Lόpez González-Cobos, C., additional, Fonseca, E., additional, Akasbi, M., additional, Pérez-de-Lis, M., additional, Jiménez-Heredia, I., additional, de la Red, G., additional, Gato, A., additional, Ramentol, M., additional, Ruedas, A., additional, Díaz-Lόpez, B., additional, Pallarés, L., additional, Gheitasi, H., additional, and Ramos-Casals, M., additional

Published
2015
Full Text
View/download PDF

8. Prevalence of HHV-8 in systemic autoimmune diseases

Author

Balada, E., primary, Ramentol, M., additional, Felip, L., additional, Ordi-Ros, J., additional, Selva-O’Callaghan, A., additional, Simeón-Aznar, C.P., additional, Solans-Laqué, R., additional, and Vilardell-Tarrés, M., additional

Published
2015
Full Text
View/download PDF

9. Model d’atenció a la salut de les persones trans*

Author

Escuriet-Peiró, Ramon, Magrinyà-Rull, Pilar, Mompart-Penina, Anna, Nadal, Cristina, Padró Pitarch, Lydia, Plaza, Aina, Ramentol-Sintas, Marc, Rubio-Cillán, Anna, Plataforma Trans*forma la salut, Almirall, Rosa, Brull, Mireia, Marin, Kenzo, Revidiego, Jordi, Vázquez, Eva, Vega, Soraya, Zapata, Diana, Godás, Teresa, Gómez, Esther, Halperin, Irene, Mora, Mireia, Raigosa, Mauricio, Vidal, Àngela, [Escuriet R, Mompart A, Rubio A] Sub-direcció General de la Cartera de Serveis i el Mapa Sanitari, Direcció General de Planificació en Salut, Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. [Magrinyà-Rull P] Direcció General de Planificació en Salut, Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. [Nadal C, Padró L] Àrea d’Atenció Sanitària del CatSalut, Subdirecció del Servei Català de la Salut, Servei Català de la Salut (CatSalut), Departament de Salut, Barcelona, Spain. [Plaza A] Gerència d’Estratègia i Comunicació, Servei Català de la Salut (CatSalut), Departament de Salut, Barcelona, Spain. [Ramentol M] Oficina d’Anàlisi i Estratègia, Gabinet de la Consellera de Salut, Departament de Salut, Barcelona, Spain. [Almirall A, Brull M, Marin K, Revidiego J, Vázquez E, Vega S, Zapata D] Unitat Trànsit, CAP Numància, Institut Català de la Salut (ICS), Barcelona, Spain. [Godás T, Gómez E, Halperin I, Mora M, Raigosa M, Vidal A] Unitat d’Identitat de Gènere, Hospital Clínic, Barcelona, Spain., and Departament de Salut

Subjects
Transsexuals - Assistència mèdica, Persons::Sexual and Gender Minorities::Transgender Persons [NAMED GROUPS], personas::minorías sexuales y de género::personas transgénero [DENOMINACIONES DE GRUPOS], derecho sanitario::derechos humanos::derecho a la salud::accesibilidad a los servicios de salud::cobertura universal de salud [SALUD PÚBLICA], Health Law::Human Rights::Right to Health::Health Services Accessibility::Universal Health Coverage [PUBLIC HEALTH], Minories sexuals - Assistència mèdica
Abstract

Persones trans; Atenció a la salut; Identitat de gènere Personas trans; Atención a la salud; Identidad de género Trans people; Health care; Gender identity L'objectiu d'aquest document és l'ordenació de la cartera de serveis de l’atenció a la salut de les persones trans en el seu procés de transició en la identitat de gènere sentida a càrrec del sistema sanitari públic de Catalunya a partir d’un model consensuat i d’un protocol clínic marc per a l’atenció de la salut.

Published
2017

11. Mental disorders, psychopharmacological treatments, and mortality in 2150 COVID-19 Spanish inpatients.

Author

Diez-Quevedo C, Iglesias-González M, Giralt-López M, Rangil T, Sanagustin D, Moreira M, López-Ramentol M, Ibáñez-Caparrós A, Lorán ME, Bustos-Cardona T, Menéndez-Cuiñas I, Mundo-Cid P, Blanco-Presas L, de Pablo J, and Cuevas-Esteban J

Subjects
COVID-19 Nucleic Acid Testing, Female, Hospital Records statistics & numerical data, Hospitalization statistics & numerical data, Humans, Male, Middle Aged, Prognosis, Recovery of Function, Risk Assessment, SARS-CoV-2 isolation & purification, Spain epidemiology, COVID-19 diagnosis, COVID-19 mortality, COVID-19 psychology, COVID-19 rehabilitation, Inpatients psychology, Inpatients statistics & numerical data, Mental Disorders diagnosis, Mental Disorders drug therapy, Mental Disorders epidemiology, Mental Disorders virology, Psychotropic Drugs classification, Psychotropic Drugs therapeutic use
Abstract

Objective: To determine how mental disorders and psychopharmacological treatments before and during COVID-19 hospital admissions are related to mortality., Methods: Subjects included in the study were all adult patients with a diagnosis of COVID-19, confirmed clinically and by PCR, who were admitted to a tertiary university hospital in Badalona (Spain) between March 1 and November 17, 2020. Data were extracted anonymously from computerized clinical records., Results: 2,150 subjects were included, 57% males, mean age 61 years. History of mental disorders was registered in 957 (45%). Throughout admission, de novo diagnosis of mood or anxiety, stress, or adjustment disorder was made in 12% of patients without previous history. Delirium was diagnosed in 10% of cases. 1011 patients (47%) received a psychotropic prescription during admission (36% benzodiazepines, 22% antidepressants, and 21% antipsychotics). Mortality rate was 17%. Delirium during admission and history of mood disorder were independently associated with higher mortality risk (hazard ratios, 1.39 and 1.52 respectively), while previous year's treatments with anxiolytics/hypnotics and antidepressants were independently associated with lower mortality risk (hazard ratios, 0.47 and 0.43, respectively)., Conclusion: Mental symptoms are very common in patients hospitalized for COVID-19 infection. Detecting, diagnosing, and treating them is key to determining the prognosis of the disease and functional recovery., (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results